|
|
|
13.10.25 - 18:18
|
Repurchase of shares in Synsam during October 6, 2025 – October 10, 2025 (week 41) (Cision)
|
|
|
Synsam AB (publ) (LEI code: 5493000TMEGW9DHNOQ70) ("Synsam" or the "Company") has during October 6, 2025, to October 10, 2025, repurchased in total 100,000 own shares (ISIN code: SE0016829709) as part of the share buy-back program initiated by the board of directors of Synsam in order to adjust the Company's capital structure.
The repurchases form part of the share buy-back program of maximum MSEK 160 announced by Synsam on August 21, 2025, and which runs during the period from August 25, 2025, until February 27, 2026. The share buy-back program is being carried out in accordance with the EU...
|
|
|
|
|
13.10.25 - 11:01
|
Invitation to media and analyst briefing for BioGaia Q3 2025 report (Cision)
|
|
|
BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2025 will be published at approximately 8:00 AM CEST on October 22, 2025.
The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/).
CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST.
To join the audiocast with teleconference and ask a...
|
|
|
|
|
13.10.25 - 10:06
|
Enzymatica appoints Holger Lembrér as new CFO (Cision)
|
|
|
Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team.
Holger Lembrér brings extensive experience as CFO and finance executive from international and publicly listed companies, primarily within the MedTech, Pharma and industrial sectors. He most recently served as CFO at Boule Diagnostics, where he held overall responsibility for the Group's finance function.
Prior to that, Holger was CFO at Oncopeptides and held several senior positions within...
|
|
|
13.10.25 - 10:06
|
Getinge′s Advanta V12 receives CE Mark for major bridging indications (Cision)
|
|
|
Getinge's Advanta™ V12 is now approved for major bridging indications, marking a milestone in complex aortic aneurysm treatment.
[image]
Today, Getinge announces that its Advanta™ V12 Covered Stent System has received CE Mark approval under the European Union Medical Device Regulation (EU MDR) for use as a bridging stent in fenestrated endovascular aneurysm repair (FEVAR), branched endovascular aneurysm repair (BEVAR), and iliac branch device (IBD) aneurysmal repair. This landmark approval offers physicians a trusted, on-label solution backed by over two decades of clinical use.
Advanta...
|
|
|
|
|
|
|
|
|
13.10.25 - 08:24
|
Intervacc and Dechra extend distribution agreement for Intervacc′s equine strangles vaccine Strangvac by two years (Cision)
|
|
|
Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will take effect in April 2026. The agreement covers Strangvac, Intervacc's vaccine against equine strangles a highly contagious infectious disease that affects horses.
Dechra Pharmaceuticals launched Strangvac in the United Kingdom during the autumn of 2022 and has since introduced the vaccine in an additional 12 countries, most recently in Spain, Portugal, and Slovenia in August this year. Intervacc...
|
|
|
12.10.25 - 22:01
|
Board Member Resigns from the Board of Episurf Medical (Cision)
|
|
|
Episurf Medical (Nasdaq: EPIS B) today announces that Annette Brodin Rampe has, at her own request, resigned from her position as a member of the Board of Directors of Episurf Medical AB due to personal reasons. Annette Brodin Rampe has served as a member of Episurf Medical's Board since 2021.
"On behalf of the Board, I would like to thank Annette for her valuable contributions over the years," says Ulf Grunander, Chairman of the Board, Episurf Medical.
For more information, please contact:
Katarina Flodström, CEO, Episurf Medical
Tel: +46 707 38 35 70
Email: katarina.flodstrom@...
|
|
|
|
|
|
|
|
|
09.10.25 - 15:18
|
Notice of Extraordinary General Meeting of Ambea AB (publ) (Cision)
|
|
|
Ambea AB (publ), Reg. No. 556468-4354, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Tuesday 4 November 2025 at 12:00 p.m. at Ambea's head office, Röntgenvägen 3 D, SE-171 54 Solna, Sweden. Registration starts at 11:30 a.m.
Notice of Extraordinary General Meeting of Ambea AB
(publ)
Ambea AB (publ), Reg. No. 556468-4354, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Tuesday 4 November 2025 at 12:00 p.m. at Ambea's head office, Röntgenvägen 3 D, SE-171 54 Solna,...
|
|
|
|
|
|
|
08.10.25 - 16:06
|
Hansa Biopharma to host Q3 2025 interim results conference call (Cision)
|
|
|
Lund, Sweden, 8 October, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - September 2025 on Thursday 30 October, 2025. Interested parties may join the Company's quarterly conference call on the same date at 13:00 CET / 8:00 EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be made...
|
|
|
08.10.25 - 14:01
|
VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase (Cision)
|
|
|
Hørsholm, Denmark, 8 October 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing innovative vaccine candidates targeting infectious diseases and cancer, today announces that the international VICI-Disease consortium has selected its lead antigen for the Nipah virus (NiV) vaccine project. The chosen antigen, derived from the Nipah virus G protein and coupled to a virus-like particle (VLP), was recently finalized as the vaccine candidate. This milestone marks the transition from discovery to pre-clinical development,...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
